OVID
Price
$1.23
Change
-$0.06 (-4.65%)
Updated
Sep 5 closing price
Capitalization
87.46M
67 days until earnings call
STOK
Price
$20.68
Change
+$1.05 (+5.35%)
Updated
Sep 5 closing price
Capitalization
1.13B
66 days until earnings call
Interact to see
Advertisement

OVID vs STOK

Header iconOVID vs STOK Comparison
Open Charts OVID vs STOKBanner chart's image
Ovid Therapeutics
Price$1.23
Change-$0.06 (-4.65%)
Volume$1.49M
Capitalization87.46M
Stoke Therapeutics
Price$20.68
Change+$1.05 (+5.35%)
Volume$543.6K
Capitalization1.13B
OVID vs STOK Comparison Chart in %
Loading...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OVID vs. STOK commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OVID is a Buy and STOK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (OVID: $1.23 vs. STOK: $20.68)
Brand notoriety: OVID and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OVID: 73% vs. STOK: 64%
Market capitalization -- OVID: $87.46M vs. STOK: $1.13B
OVID [@Biotechnology] is valued at $87.46M. STOK’s [@Biotechnology] market capitalization is $1.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OVID’s FA Score shows that 1 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • OVID’s FA Score: 1 green, 4 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than OVID.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OVID’s TA Score shows that 5 TA indicator(s) are bullish while STOK’s TA Score has 3 bullish TA indicator(s).

  • OVID’s TA Score: 5 bullish, 4 bearish.
  • STOK’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, OVID is a better buy in the short-term than STOK.

Price Growth

OVID (@Biotechnology) experienced а -3.91% price change this week, while STOK (@Biotechnology) price change was +4.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

OVID is expected to report earnings on Nov 12, 2025.

STOK is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($1.13B) has a higher market cap than OVID($87.5M). STOK YTD gains are higher at: 87.489 vs. OVID (31.734). STOK has higher annual earnings (EBITDA): 42.3M vs. OVID (-41.01M). STOK has more cash in the bank: 248M vs. OVID (38.3M). STOK has less debt than OVID: STOK (2.3M) vs OVID (14.1M). STOK has higher revenues than OVID: STOK (200M) vs OVID (6.65M).
OVIDSTOKOVID / STOK
Capitalization87.5M1.13B8%
EBITDA-41.01M42.3M-97%
Gain YTD31.73487.48936%
P/E RatioN/A23.77-
Revenue6.65M200M3%
Total Cash38.3M248M15%
Total Debt14.1M2.3M614%
FUNDAMENTALS RATINGS
OVID vs STOK: Fundamental Ratings
OVID
STOK
OUTLOOK RATING
1..100
2582
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9846
PRICE GROWTH RATING
1..100
3435
P/E GROWTH RATING
1..100
949
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OVID's Valuation (25) in the Pharmaceuticals Major industry is somewhat better than the same rating for STOK (60) in the null industry. This means that OVID’s stock grew somewhat faster than STOK’s over the last 12 months.

OVID's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as STOK (100) in the null industry. This means that OVID’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (46) in the null industry is somewhat better than the same rating for OVID (98) in the Pharmaceuticals Major industry. This means that STOK’s stock grew somewhat faster than OVID’s over the last 12 months.

OVID's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as STOK (35) in the null industry. This means that OVID’s stock grew similarly to STOK’s over the last 12 months.

STOK's P/E Growth Rating (9) in the null industry is significantly better than the same rating for OVID (94) in the Pharmaceuticals Major industry. This means that STOK’s stock grew significantly faster than OVID’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OVIDSTOK
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
75%
Bullish Trend 17 days ago
86%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 5 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DNIYY33.48N/A
N/A
Danieli S.p.A.- Officine Meccaniche Danieli & C.
HAOTF0.14N/A
N/A
HAO TIAN INTL CONSTR INVT GROUP LTD.
PTEEF0.05N/A
N/A
Plaintree Systems Inc.
RKUNY6.06-0.08
-1.30%
Rakuten Group Inc.
AAUAF0.19-0.02
-7.63%
Almaden Minerals Ltd.

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with JBIO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then JBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
-4.65%
JBIO - OVID
79%
Closely correlated
-0.13%
ARCT - OVID
46%
Loosely correlated
+6.50%
GBIO - OVID
43%
Loosely correlated
+3.63%
DNLI - OVID
42%
Loosely correlated
+4.33%
BEAM - OVID
41%
Loosely correlated
+12.62%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
+5.35%
IDYA - STOK
50%
Loosely correlated
+5.15%
QTTB - STOK
49%
Loosely correlated
+0.60%
SYRE - STOK
47%
Loosely correlated
+0.06%
IMNM - STOK
47%
Loosely correlated
+7.35%
DNLI - STOK
46%
Loosely correlated
+4.33%
More